Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results
Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).
Study results suggest that switching to a TAF (tenofovir alafenamide)-based regimen is generally safer than continuing to take TDF (tenofovir disoproxil fumarate)-containing regimens, particularly for bone and kidney health.
In general, tenofovir alafenamide (TAF) is safe, with improvements in bone and kidney health over tenofovir disoproxil fumarate (TDF). However, those with severe kidney disease may not see improvements in kidney health, according to a recent study....
In this interview, Joel E. Gallant, M.D., M.P.H., discusses new HIV drugs in the pipeline and the lack of young people becoming HIV care specialists.
We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.